AstraZeneca’s asthma drug tralokinumab goes 0 for 3 in PhIII as 2 more trials flop
You can write off just about all of the remaining value assigned to AstraZeneca’s asthma drug tralokinumab — if you hadn’t already done so. Outside of the cancer arena, AstraZeneca’s string of setbacks is continuing.
The pharma giant followed up yesterday’s news that its BTK drug Calquence (acalabrutinib) had scored an early approval at the FDA with a note writing off the last two Phase III studies of their IL-13 drug tralokinumab as failures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.